Want to see GLUE full AI Analyst Report?
GLUE Stock Chart & Stats
$22.78
$0.07(0.31%)
At close: 4:00 PM EDT
$22.78
$0.07(0.31%)
Day’s Range― - ―
52-Week Range$4.30 - $25.77
Previous CloseN/A
Volume570.68K
Average Volume (3M)1.46M
Market Cap
$1.36B
Enterprise Value$1.87K
Total Cash (Recent Filing)$621.10M
Total Debt (Recent Filing)$37.99M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 05, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding85,313,400
10 Day Avg. Volume989,457
30 Day Avg. Volume1,455,750
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)4.41
Price to Sales (P/S)8.31
P/FCF Ratio-37.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.83Price Target Upside26.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$44.46M
Bulls Say, Bears Say
Bulls Say
Proprietary Degrader PlatformA proprietary molecular glue degrader platform is a durable competitive asset: it enables discovery of differentiated small-molecule programs across indications, supports multiple pipeline assets, and creates persistent licensing and partnership optionality that can sustain value creation beyond any single program.
Mid‑stage Clinical Progress & Novartis CollaborationActivation of Phase 2 trials and a Novartis‑led Phase 2 for MRT-6160 materially de-risks select programs. Mid‑stage progress plus an established big‑pharma collaborator increases likelihood of milestone payments, validates biology, and raises the odds of strategic exits or further partnerships over the medium term.
Very High Gross MarginsReported TTM gross margins near 95% indicate strong unit economics for successful programs. If Monte Rosa advances a candidate to commercial stages, these structural margins imply attractive operating leverage and potential for durable profitability once revenue scales and fixed R&D overheads are absorbed.
Bears Say
Sharp Revenue DeclineA steep 33% TTM revenue drop signals volatile and uneven near‑term cash inflows from collaborations or milestones. For a clinical‑stage biotech, inconsistent partner receipts heighten financing risk and make executing multi‑year development plans harder without frequent external funding events.
Large Losses And Ongoing Cash BurnSubstantial net losses and persistent negative operating and free cash flow require repeated financing or milestone receipts. Over months this pressures runway, risks dilution from equity raises, and can constrain R&D prioritization unless clinical progress or partner funding materially improves cash generation.
Dependence On Collaborations, No Commercial SalesAs a clinical‑stage company without commercial products, revenue is episodic and tied to partner deals and milestones. This structural reliance increases exposure to partner timing, trial outcomes, and negotiation cycles, making long‑term revenue visibility and self‑funded development less certain.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics, Inc.’s price range in the past 12 months?
Monte Rosa Therapeutics, Inc. lowest stock price was $4.30 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics, Inc.’s market cap?
Monte Rosa Therapeutics, Inc.’s market cap is $1.36B.
When is Monte Rosa Therapeutics, Inc.’s upcoming earnings report date?
Monte Rosa Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Monte Rosa Therapeutics, Inc.’s earnings last quarter?
Monte Rosa Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.05.
Is Monte Rosa Therapeutics, Inc. overvalued?
According to Wall Street analysts Monte Rosa Therapeutics, Inc.’s price is currently Undervalued.
Does Monte Rosa Therapeutics, Inc. pay dividends?
Monte Rosa Therapeutics, Inc. does not currently pay dividends.
What is Monte Rosa Therapeutics, Inc.’s EPS estimate?
Monte Rosa Therapeutics, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Monte Rosa Therapeutics, Inc. have?
Monte Rosa Therapeutics, Inc. has 85,313,400 shares outstanding.
What happened to Monte Rosa Therapeutics, Inc.’s price movement after its last earnings report?
Monte Rosa Therapeutics, Inc. reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went up 0.641%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.83 (26.57% Upside)
$28.83 (26.57% Upside)
Blogger Sentiment
Neutral
GLUE Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 666.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $631.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
298.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
92.21%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$28.83
▲(26.57% Upside)
Technical Analysis
CytomX Therapeutics
―
Fulcrum Therapeutics
―
Monopar Therapeutics Inc
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.88% Insiders
14.97% Mutual Funds
8.60% Other Institutional Investors
51.70% Public Companies and
Individual Investors